|
|||||||
|
Fusion Protein:ANKRD52-DYRK2 |
Fusion Gene and Fusion Protein Summary |
 Fusion gene summary |
| Fusion partner gene information | Fusion gene name: ANKRD52-DYRK2 | FusionPDB ID: 4765 | FusionGDB2.0 ID: 4765 | Hgene | Tgene | Gene symbol | ANKRD52 | DYRK2 | Gene ID | 283373 | 8445 |
| Gene name | ankyrin repeat domain 52 | dual specificity tyrosine phosphorylation regulated kinase 2 | |
| Synonyms | ANKRD33 | - | |
| Cytomap | 12q13.3 | 12q15 | |
| Type of gene | protein-coding | protein-coding | |
| Description | serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit CCVWG5837PP6-ARS-Cankyrin repeat domain 33ankyrin repeat domain-containing protein 52protein phosphatase 6 ankyrin repeat subunit Cserine/threonine-protein phosphatase 6 regula | dual specificity tyrosine-phosphorylation-regulated kinase 2dual specificity tyrosine-(Y)-phosphorylation regulated kinase 2 | |
| Modification date | 20200313 | 20200313 | |
| UniProtAcc | Q8NB46 Main function of 5'-partner protein: FUNCTION: Putative regulatory subunit of protein phosphatase 6 (PP6) that may be involved in the recognition of phosphoprotein substrates. | Q92630 Main function of 5'-partner protein: FUNCTION: Serine/threonine-protein kinase involved in the regulation of the mitotic cell cycle, cell proliferation, apoptosis, organization of the cytoskeleton and neurite outgrowth. Functions in part via its role in ubiquitin-dependent proteasomal protein degradation. Functions downstream of ATM and phosphorylates p53/TP53 at 'Ser-46', and thereby contributes to the induction of apoptosis in response to DNA damage. Phosphorylates NFATC1, and thereby inhibits its accumulation in the nucleus and its transcription factor activity. Phosphorylates EIF2B5 at 'Ser-544', enabling its subsequent phosphorylation and inhibition by GSK3B. Likewise, phosphorylation of NFATC1, CRMP2/DPYSL2 and CRMP4/DPYSL3 promotes their subsequent phosphorylation by GSK3B. May play a general role in the priming of GSK3 substrates. Inactivates GYS1 by phosphorylation at 'Ser-641', and potentially also a second phosphorylation site, thus regulating glycogen synthesis. Mediates EDVP E3 ligase complex formation and is required for the phosphorylation and subsequent degradation of KATNA1. Phosphorylates TERT at 'Ser-457', promoting TERT ubiquitination by the EDVP complex. Phosphorylates SIAH2, and thereby increases its ubiquitin ligase activity. Promotes the proteasomal degradation of MYC and JUN, and thereby regulates progress through the mitotic cell cycle and cell proliferation. Promotes proteasomal degradation of GLI2 and GLI3, and thereby plays a role in smoothened and sonic hedgehog signaling. Plays a role in cytoskeleton organization and neurite outgrowth via its phosphorylation of DCX and DPYSL2. Phosphorylates CRMP2/DPYSL2, CRMP4/DPYSL3, DCX, EIF2B5, EIF4EBP1, GLI2, GLI3, GYS1, JUN, MDM2, MYC, NFATC1, p53/TP53, TAU/MAPT and KATNA1. Can phosphorylate histone H1, histone H3 and histone H2B (in vitro). Can phosphorylate CARHSP1 (in vitro). {ECO:0000269|PubMed:11311121, ECO:0000269|PubMed:12588975, ECO:0000269|PubMed:14593110, ECO:0000269|PubMed:15910284, ECO:0000269|PubMed:16511445, ECO:0000269|PubMed:16611631, ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:18455992, ECO:0000269|PubMed:18599021, ECO:0000269|PubMed:19287380, ECO:0000269|PubMed:22307329, ECO:0000269|PubMed:22878263, ECO:0000269|PubMed:23362280, ECO:0000269|PubMed:9748265}. | |
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000267116, ENST00000548241, | ENST00000393555, ENST00000537632, ENST00000344096, |
| Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0) | * DoF score | 12 X 13 X 5=780 | 8 X 5 X 7=280 |
| # samples | 11 | 8 | |
| ** MAII score | log2(11/780*10)=-2.82597060022495 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(8/280*10)=-1.8073549220576 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Fusion gene context | PubMed: ANKRD52 [Title/Abstract] AND DYRK2 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Fusion neoantigen context | PubMed: ANKRD52 [Title/Abstract] AND DYRK2 [Title/Abstract] AND neoantigen [Title/Abstract] | ||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | ANKRD52(56641277)-DYRK2(68050886), # samples:2 | ||
| Anticipated loss of major functional domain due to fusion event. | ANKRD52-DYRK2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ANKRD52-DYRK2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | DYRK2 | GO:0006468 | protein phosphorylation | 11311121 |
| Tgene | DYRK2 | GO:0042771 | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 17349958 |
| Tgene | DYRK2 | GO:0045725 | positive regulation of glycogen biosynthetic process | 11311121 |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr12:56641277/chr12:68050886) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here. |
| Fusion gene breakpoints across ANKRD52 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene breakpoints across DYRK2 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
Top |
Fusion Amino Acid Sequences |
| Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000267116 | ANKRD52 | chr12 | 56641277 | - | ENST00000344096 | DYRK2 | chr12 | 68050886 | + | 10607 | 2306 | 44 | 3913 | 1289 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000267116 | ENST00000344096 | ANKRD52 | chr12 | 56641277 | - | DYRK2 | chr12 | 68050886 | + | 0.00015869 | 0.99984133 |
| Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones. |
Get the fusion protein sequences from here. |
| Fusion protein sequence information is available in the fasta format. >FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP |
Top |
Fusion Protein Breakpoint Sequences for ANKRD52-DYRK2 |
| +/-13 AA sequence from the breakpoints of the fusion protein sequences. |
| Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Length(fusion protein) | BP in fusion protein | Peptide |
| ANKRD52 | chr12 | 56641277 | DYRK2 | chr12 | 68050886 | 2306 | 754 | AADLRGRTALHRGIGGSKHTMNDHLH |
Top |
Potential FusionNeoAntigen Information of ANKRD52-DYRK2 in HLA I |
| Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific. |
| ANKRD52-DYRK2_56641277_68050886.msa |
| Potential FusionNeoAntigen Information * We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5) |
| Fusion gene | Hchr | Hbp | Tgene | Tchr | Tbp | HLA I | FusionNeoAntigen peptide | Binding score | Immunogenic score | Neoantigen start (at BP 13) | Neoantigen end (at BP 13) |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | HLA-B27:04 | GRTALHRGI | 0.999 | 0.5851 | 5 | 14 |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | HLA-A03:25 | ALHRGIGGSK | 0.9815 | 0.5903 | 8 | 18 |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | HLA-A03:01 | ALHRGIGGSK | 0.9815 | 0.5903 | 8 | 18 |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | HLA-B27:06 | GRTALHRGI | 0.9988 | 0.6102 | 5 | 14 |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | HLA-B27:09 | GRTALHRGI | 0.998 | 0.5457 | 5 | 14 |
Top |
Potential FusionNeoAntigen Information of ANKRD52-DYRK2 in HLA II |
| Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific. |
| ANKRD52-DYRK2_56641277_68050886.msa |
| Potential FusionNeoAntigen Information * We used NetMHCIIpan v4.1 (%rank<0.5). |
| Fusion gene | Hchr | Hbp | Tgene | Tchr | Tbp | HLA II | FusionNeoAntigen peptide | Neoantigen start (at BP 13) | Neoantigen end (at BP 13) |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | DRB1-1102 | AADLRGRTALHRGIG | 0 | 15 |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | DRB1-1116 | AADLRGRTALHRGIG | 0 | 15 |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | DRB1-1121 | AADLRGRTALHRGIG | 0 | 15 |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | DRB1-1155 | AADLRGRTALHRGIG | 0 | 15 |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | DRB1-1165 | AADLRGRTALHRGIG | 0 | 15 |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | DRB1-1170 | AADLRGRTALHRGIG | 0 | 15 |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | DRB1-1301 | AADLRGRTALHRGIG | 0 | 15 |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | DRB1-1315 | AADLRGRTALHRGIG | 0 | 15 |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | DRB1-1317 | AADLRGRTALHRGIG | 0 | 15 |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | DRB1-1319 | AADLRGRTALHRGIG | 0 | 15 |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | DRB1-1322 | AADLRGRTALHRGIG | 0 | 15 |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | DRB1-1335 | AADLRGRTALHRGIG | 0 | 15 |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | DRB1-1351 | AADLRGRTALHRGIG | 0 | 15 |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | DRB1-1352 | AADLRGRTALHRGIG | 0 | 15 |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | DRB1-1353 | AADLRGRTALHRGIG | 0 | 15 |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | DRB1-1357 | AADLRGRTALHRGIG | 0 | 15 |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | DRB1-1359 | AADLRGRTALHRGIG | 0 | 15 |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | DRB1-1361 | AADLRGRTALHRGIG | 0 | 15 |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | DRB1-1364 | AADLRGRTALHRGIG | 0 | 15 |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | DRB1-1368 | AADLRGRTALHRGIG | 0 | 15 |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | DRB1-1369 | AADLRGRTALHRGIG | 0 | 15 |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | DRB1-1379 | AADLRGRTALHRGIG | 0 | 15 |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | DRB1-1380 | AADLRGRTALHRGIG | 0 | 15 |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | DRB1-1383 | AADLRGRTALHRGIG | 0 | 15 |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | DRB1-1387 | AADLRGRTALHRGIG | 0 | 15 |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | DRB1-1391 | AADLRGRTALHRGIG | 0 | 15 |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | DRB1-1392 | AADLRGRTALHRGIG | 0 | 15 |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | DRB1-1398 | AADLRGRTALHRGIG | 0 | 15 |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 | DRB5-0103 | AADLRGRTALHRGIG | 0 | 15 |
Top |
Fusion breakpoint peptide structures of ANKRD52-DYRK2 |
| 3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens * The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA. |
| File name | BPseq | Hgene | Tgene | Hchr | Hbp | Tchr | Tbp | AAlen |
| 8263 | RTALHRGIGGSKHT | ANKRD52 | DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 2306 |
Top |
Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ANKRD52-DYRK2 |
| Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens * We used Glide to predict the interaction between HLAs and neoantigens. |
| HLA allele | PDB ID | File name | BPseq | Docking score | Glide score |
| HLA-B14:02 | 3BVN | 8263 | RTALHRGIGGSKHT | -3.07948 | -3.07948 |
| HLA-A24:02 | 5HGA | 8263 | RTALHRGIGGSKHT | -4.26901 | -4.26901 |
Top |
Vaccine Design for the FusionNeoAntigens of ANKRD52-DYRK2 |
| mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is. |
| Fusion gene | Hchr | Hbp | Tchr | Tbp | Start in +/-13AA | End in +/-13AA | FusionNeoAntigen peptide sequence | FusionNeoAntigen RNA sequence |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 5 | 14 | GRTALHRGI | GGCCGCACTGCCCTCCACCGCGGGATT |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 8 | 18 | ALHRGIGGSK | GCCCTCCACCGCGGGATTGGCGGCAGTAAG |
| mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs. |
| Fusion gene | Hchr | Hbp | Tchr | Tbp | Start in +/-13AA | End in +/-13AA | FusionNeoAntigen peptide | FusionNEoAntigen RNA sequence |
| ANKRD52-DYRK2 | chr12 | 56641277 | chr12 | 68050886 | 0 | 15 | AADLRGRTALHRGIG | GCTGCTGACCTCCGGGGCCGCACTGCCCTCCACCGCGGGATTGGC |
Top |
Information of the samples that have these potential fusion neoantigens of ANKRD52-DYRK2 |
| These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens. |
| Cancer type | Fusion gene | Hchr | Hbp | Henst | Tchr | Tbp | Tenst | Sample |
| ACC | ANKRD52-DYRK2 | chr12 | 56641277 | ENST00000267116 | chr12 | 68050886 | ENST00000344096 | TCGA-OR-A5K9-01A |
Top |
Potential target of CAR-T therapy development for ANKRD52-DYRK2 |
| Predicted 3D structure. We used RoseTTAFold. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features * Minus value of BPloci means that the break point is located before the CDS. |
| - In-frame and retained 'Transmembrane'. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Subcellular localization prediction of the transmembrane domain retained fusion proteins * We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image. |
| Hgene | Hchr | Hbp | Henst | Tgene | Tchr | Tbp | Tenst | DeepLoc result |
Top |
Related Drugs to ANKRD52-DYRK2 |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
Top |
Related Diseases to ANKRD52-DYRK2 |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Copyright 2023-PresentThe University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information
Campus Carry|Site Policies